Integer (US:ITGR)2026-02-19 13:14Financial Performance - Integer Holdings Corporation achieved 8% sales growth and 21% adjusted EPS growth for the full year 2025 compared to 2024[1][4] - In Q4 2025, Cardio & Vascular sales increased 11% to $284 million, while full year sales rose 17% to $1.107 billion[5][21] - Adjusted operating income for 2025 increased by 13% to $321 million, with adjusted net income rising 23% to $226 million[6][19] - Integer Holdings Corporation reported Q4 2025 sales of $472.06 million, a 5.7% increase from $449.50 million in Q4 2024[37] - For the full year 2025, sales reached $1.85 billion, up 8.0% from $1.72 billion in 2024[37] - Gross profit for Q4 2025 was $124,756 thousand, up from $116,796 thousand in Q4 2024, representing a 8.4% increase[38] - Operating income for the year ended December 31, 2025, was $221,264 thousand, compared to $208,238 thousand in 2024, reflecting a 6.4% growth[38] - Net income for 2025 was $102,808 thousand, down from $119,896 thousand in 2024, indicating a decrease of 14.3%[39] - Adjusted net income (Non-GAAP) for 2025 was $272,526 thousand, compared to $224,747 thousand in 2024, reflecting a 21.2% increase[42] Sales and Market Trends - The company expects 2026 sales guidance in the range of $1.826 billion to $1.876 billion, reflecting a slight decline of 1% to an increase of 1% from 2025[9] - Adjusted EPS for 2026 is projected to be between $6.29 and $6.78, indicating a decrease of 2% to an increase of 6% compared to 2025[9] - Cardiac Rhythm Management & Neuromodulation sales decreased 2% to $167 million in Q4 2025, while full year sales increased by 1% to $669 million[13][21] - Other Markets sales fell 13% to $21 million in Q4 2025, with a full year decline of 27% to $78 million[13][21] - Integer anticipates returning to 200 basis points above-market organic sales growth in 2027[4] - The company experienced a total sales growth of 5.0% in Q4 2025 compared to Q4 2024, with organic sales change of 2.0% after adjusting for foreign currency and acquisitions[58] - Cardio & Vascular segment sales grew by 11.3% in Q4 2025, while the Cardiac Rhythm Management & Neuromodulation segment saw a decline of 1.9%[58] Debt and Financial Position - Total debt increased by $195 million to $1.185 billion, resulting in a leverage ratio of 3.0 times adjusted EBITDA as of December 31, 2025[6] - Integer's net total debt was $1.19 billion as of December 31, 2025, compared to $990.15 million in 2024, indicating a 20.1% increase[36] - Total debt increased to $1,185,179,000 as of December 31, 2025, from $990,153,000 in 2024, resulting in a net total debt of $1,190,123,000, up from $954,451,000[61] Shareholder Activities - Integer plans to repurchase approximately $50 million of its common stock as part of an accelerated share repurchase program[8] - The company plans to engage in share repurchase activities, including an Accelerated Share Repurchase (ASR) program[31] Operational Efficiency and Costs - The company incurred $46,681 thousand in debt conversion inducement expense in 2025, which was not present in 2024[39] - The company incurred restructuring and restructuring-related charges of $3,767,000 in Q4 2025, compared to $1,517,000 in Q4 2024, indicating increased costs associated with realignment efforts[54] - The implementation of a new global ERP solution incurred costs of $1,651,000 in 2025, indicating a significant investment in operational efficiency[54] - The company recorded leadership transition costs of $2,400,000 in Q4 2025 and $4,100,000 for the year, reflecting ongoing strategic adjustments[50] Cash Flow and Assets - Cash flows from operating activities for 2025 totaled $196,148 thousand, slightly down from $205,205 thousand in 2024[40] - The company’s total assets increased to $3.41 billion in 2025, compared to $3.08 billion in 2024, reflecting a growth of 10.8%[36] - Current assets rose to $770.10 million in 2025, up from $671.12 million in 2024, marking a 14.8% increase[36] - Integer's cash and cash equivalents decreased to $17.16 million in 2025 from $46.54 million in 2024, a decline of 63.2%[36] - Cash and cash equivalents at the end of 2025 were $17,161 thousand, a decrease from $46,543 thousand at the end of 2024[40] Future Outlook - Adjusted EBITDA for the year is expected to reflect continued growth, supporting the company's strategy to enhance shareholder value[31] - The company anticipates a return to above-market organic sales growth in 2027, driven by new product developments and market expansions[31]